This article has Open Peer Review reports available.
The extracellular matrix protein mindin as a novel adjuvant elicits stronger immune responses for rBAG1, rSRS4 and rSRS9 antigens of Toxoplasma gondiiin BALB/c mice
- Xiaojing Sun†1,
- Mei Mei†2,
- Xu Zhang1,
- Fusong Han1,
- Boyin Jia1,
- Xiaoyan Wei1,
- Zhiguang Chang1,
- Huijun Lu1,
- Jigang Yin1,
- Qijun Chen1Email author and
- Ning Jiang1Email author
© Sun et al.; licensee BioMed Central Ltd. 2014
Received: 6 March 2014
Accepted: 18 July 2014
Published: 4 August 2014
Vaccines are the most effective agents to control infections. However, recombinant vaccines often do not elicit strong immune responses. Protein antigens combined with proper adjuvants have been widely used to induce immune responses, especially the humoral immune responses, against various pathogens, including parasites. The extracellular matrix protein mindin has been recognised as an immune facilitator for initiating innate immune responses. It has therefore been expected to be a potentially potent adjuvant in the development of novel vaccines. The aim of this study was to investigate whether mindin could facilitate the induction of antigen-specific immune responses to recombinant antigens (rBAG1, rSRS4 and rSRS9) of Toxoplasma gondii in BALB/c mice.
In this study, we explored the adjuvant effect of the recombinant mindin in the generation of specific Th1 and Th2 responses to each of three T. gondii antigens, BAG1, SRS4 and SRS9. All mice in the experimental groups received either antigen alone or in combination with Freund’s adjuvant or with the recombinant mindin. The immune responses after immunisation were measured by ELISA and lymphoproliferative assays. The immunised mice were challenged with live T. gondii tachyzoites, and the protection efficiency was compared between the groups.
Our results revealed that mindin as an adjuvant could facilitate the recombinant proteins to efficiently stimulate humoral and cellular responses, including antigen-specific IgG1 and IgG2a, as well as lymphocyte proliferation. Furthermore, significantly improved protection against T. gondii infection was observed in the mindin group compared with that of Freund’s adjuvant and no-adjuvant groups.
The extracellular matrix protein mindin can effectively induce antigen-specific humoral and cell-mediated immune responses. Our study provides a valuable basis for the development of an efficient, safe, non-toxic vaccine adjuvant for future use in humans and animals.
Vaccine adjuvants facilitate the production of long-lasting, efficient and specific immune responses and improve the protective effect of vaccines due to a higher antibody yield and the persistence of antibodies, as well as functional T cells at high levels. Currently, the most common adjuvant used in experimental animals is Freund’s adjuvants, which can enhance strong antigen-specific immune responses. However, it causes strong inflammation and necrosis at the injection site, which prevents its use in vaccine development. Aluminium-derived adjuvants are often used in clinical trials and have the reputation of safety and the facilitation of long-lasting antibody responses , but the effect on cell-mediated immunity remains questionable when used along with small immunogenic antigens. To develop safe and effective adjuvants for enhancing both humoral and cellular immune responses, we focused on the selection of novel immunofacilitators based on their roles in initiating innate and adaptive immune responses.
Mindin (also known as spondin 2) belongs to the mindin-F-spondin family of secreted extracellular matrix (ECM) proteins that includes mammalian F-spodin, zebrafish mindin 1 and 2, and Drosophila M-spondin [2–5]. Mindin has been known to essentially initiate innate immunity and serve as a bridge between innate and adaptive immunity . Previous reports indicated that mindin-deficient mice had an impaired capability to clear influenza virus and bacterial infection, and mindin-deficient macrophages exhibit defective responses to a broad spectrum of microbial stimuli. This is because mindin is a pattern recognition molecule and can directly bind to sugar moieties in bacterial cell walls  and influenza virus particles to initiate innate immune responses, as well as function as an opsonin for macrophage phagocytosis of bacteria . Interestingly, even recombinant mindin alone is capable of promoting viral clearance in wild-type mice . Possible mechanisms for mindin’s effects on immunity system include binding to a cell surface receptor, activating synergistic signal transduction pathways for proinflammatory cytokine production, interacting with other pattern recognition receptors (PRR) (such as the Toll-like receptors) and enhancing their recognition of bacterial products, inducing bacterial phagocytosis to enhance the immune response to infection, or a combination of these mechanisms . Based on these findings, mindin has been considered as a novel vaccine adjuvant candidate in view of its superior immune-enhancing capabilities.
Toxoplasma gondii, a member of the Apicomplexa phylum, is an obligatory intracellular and opportunistic parasite that infects both warm-blooded animals and human beings to cause toxoplasmosis . This parasite is a highly prevalent, zoonotic pathogen of medical, veterinary and economic importance [10, 11]. Acquired toxoplasmosis is usually an asymptomatic disease of adults, which most likely persists for the lifetime of the hosts. However, this disease can be quite severe or even fatal for immunocompromised patients, such as those with AIDS, organ transplant recipients, or those with neoplastic diseases [12, 13], and the sequelae associated with diseases include blinding chorioretinitis, lymphadenopathy, encephalitis and/or death . Toxoplasmosis has long been a disease of worldwide importance for public health and economic development. Consequently, the development of an effective vaccine for controlling the impact of this disease is urgently needed.
Currently, the best developed vaccine is the live, attenuated tachyzoite S48 , which has not been widely applied because of its high cost, side effects, and short shelf life. More importantly, attenuated vaccines carry a risk of unexpected harmful reverse mutations and accidental infections of humans . To overcome these issues, most of current research has been focused on searching for subunit or recombinant vaccines. The SAG1-related sequence (SRS) super-family, encoding glycophosphatidylinositol (GPI)-anchored surface proteins , are the crucial surface antigens of T. gondii that participate in the process of host cell attachment and regulate the virulence of these parasites, which could be a promising vaccine candidate against toxoplasmosis . Furthermore, the SRS9 molecule, a bradyzoite-specific SRS antigen, has been suggested to be an important target of the host immune response in the mouse intestine . SRS4 has been shown to be able to elicit strong antibody responses in humans infected by T. gondii and has been considered as a diagnostic and/or vaccine antigen [20, 21]. In addition, BAG1, a T. gondii 30-kDa cytosolic heat-shock protein, preferentially expressed at the bradyzoite stage, is very immunogenic because of its induction of early humoral and cell-mediated immune responses upon infection in humans [22–24]. Therefore, we chose BAG1, SRS4 and SRS9 of T. gondii as vaccine candidates to assess the immune-enhancing effect of mindin. The function of mindin as a novel adjuvant for the T. gondii antigens BAG1, SRS4 and SRS9 was evaluated through an analysis of the induction of antigen-specific antibodies, lymphocyte proliferation and the immune protection capacity in challenge experiments. The results showed that the extracellular matrix protein mindin is a very potent adjuvant molecule owing to its enhancement of both humoral and cell-mediated immune responses.
Animals and parasites
Female BALB/c and male Kunming strain outbred mice aged 8 to 10 weeks were used in all experiments. Kunming mice were used to maintain and passage T. gondii tachyzoites, whereas BALB/c mice were used in the immunisation experiments. The permission to work with laboratory animals was obtained from the Ethical Committee of the Institute of Zoonosis, Jilin University, China (Permission number 2008-IZ-20). Tachyzoites of the RH strain of T. gondii were harvested from the peritoneal fluid of Kunming mice after intraperitoneal infection.
Generation of recombinant proteins
The Mus musculus spon 2 gene-encoding extracellular matrix protein mindin was chemically synthesised with restriction sites (BamHI and HindIII) at the 5′ and 3′ ends, respectively. The gene fragment was subcloned into the plasmid pET-22b (Qiagen, Düsseldorf, Germany) to construct an expression plasmid, which was subsequently confirmed by enzymatic digestion and sequencing. After transformation of the plasmid into BL21 (DE3) competent cells, the expression of the His-tag fusion protein was induced by the addition of IPTG at 37°C for 5 h. The recombinant protein in inclusion bodies was purified by Ni-affinity chromatography (GE Healthsystems, Uppsala, Sweden) according to the manufacturer’s instructions. The inclusion bodies were solubilised by 6 M urea, and the purified, denatured mindin was refolded by dialysis in PBS containing urea (initial concentration was 6 M, then decreased by 1 M/dialysis) and 0.5 M arginine. Subsequently, the refolded protein was dialysed 5 times against the dialysis buffer to remove arginine changing from 0.5 M-0 M buffers, 12 h/time-point. Finally, the protein was confirmed by SDS-PAGE and Western blotting.
The recombinant T. gondii antigens (rBAG1, rSRS4 and rSRS9) were generated as described in our previous study .
Immunisation schedule and serum collection
Animals were immunised with one of the three recombinant antigens (rBAG1, rSRS4 and rSRS9) formulated with complete Freund’s adjuvant (CFA)/incomplete Freund’s adjuvant (IFA) (Sigma–Aldrich, St. Louis, MO, USA), the recombinant protein mindin or PBS. To formulate the Freund’s adjuvant emulsion, the antigens were mixed with an equal volume of adjuvant solution in two syringes connected with an adaptor (Sigma). Each test group contained eleven mice and the control groups with the same number of animals receiving the CFA/IFA, mindin or PBS alone, respectively.
All mice were immunised intramuscularly with the antigen-adjuvant mixtures on weeks 2, 4, 6 and 8. The amount of each recombinant antigen used for each immunisation was 20 μg/mouse. Serum samples were collected from all animals in each group prior to the first immunisation and 10 days after each immunisation. Sera were separated from blood by centrifugation at 2000 rpm for 15 min and stored at −80°C until further analysis.
Detection of specific antibody responses by ELISA
IgG levels in the collected sera were determined by an enzyme-linked immunosorbent assay (ELISA). Maxisor micro-ELISA plates (Nalge Nunc International, IL, USA) were coated with 50 μl per well of the T. gondii recombinant antigens (rBAG1, rSRS4 and rSRS9, respectively) in a concentration of 5 μg/ml at 4°C overnight. The plates were washed four times with PBS containing 0.05% Tween 20 and blocked for 1 h at 37°C with 100 μl per well of 3% bovine serum albumin (BSA) in coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). The sera of immunised mice diluted from 1:1000 to 1:128,000 were added in triplicate and allowed to incubate for 1 h at 37°C. Plates were washed, and bound IgG was detected by incubation for 1 h with alkaline phosphatase-conjugated goat anti-mouse IgG (1:20,000, Sigma). Finally, 50 μl of pNPP [4-Nitrophenyl phosphate disodium salt hexahydrate] (Sigma, St. Louis, USA) and 9.7% diethanolamine (pH 9.8) were used to detect antigen-antibody reactions. The optical density (OD) was read at 405 nm in a Biotek micro-ELISA auto-reader 808 (Bio-TEK Instruments, Winooski, USA).
For typing the IgG subclasses, the three fusion proteins were each coated on ELISA plates as described previously and incubated with sera (1:1000) from immunised mice. Antigen-specific IgG subclasses were thereafter identified with commercial kits (BioLegend San Diego, CA, USA) according to the protocols provided by the manufacturer.
Lymphocyte proliferation assays
Three mice from each group were euthanised two weeks after the last immunisation. Their spleens were removed under sterile conditions. Single-cell suspensions were obtained by filtration through a 200-mesh copper grid. After separation with mouse Percoll (Sigma) used according to the manufacturer’s instructions, the remaining splenocyte suspensions were diluted to a final concentration of 5 × 106 cells/ml in RPMI 1640 with 10% foetal bovine serum (Sigma). Splenocyte suspensions (100 μl/well) were plated into 96-well cell culture plates. The cells were stimulated with 20 μg/ml rBAG1, rSRS4 and rSRS9 at 37°C for 60–72 h in the presence of 5% CO2 followed by the addition of 10 μl/well MTT solutions (5 mg/ml). The plates were then incubated for 4 h at 37°C followed by an addition of 150 μl/well DMSO solution. The sample absorbance at 570 nm was then measured. Concanavalin A (10 μg/ml, Sigma) was used as a positive control, and cells cultured with media alone were used as negative controls. The growth index was calculated according to the formula, Growth Index (GI) = (ODtest-ODnegative)/(ODpositive)-ODnegative).
Eight mice in each group were challenged intraperitoneally with 250 tachyzoites of T. gondii RH strain/mouse 2 weeks after the last immunisation. The mice were carefully observed for 20 days.
GraphPad Prism 5 (GraphPad InStatt Software, San Diego, California) and one-factor analysis of variance (ANOVA) were used in this study. Data are expressed as the mean ± standard deviation (SD). The differences between groups were considered to be significant when the P value was less than 0.05. The Kaplan-Meier survival curves were generated with the MedCalc statistical software (http://www.medcalc.org/manual/kaplan-meier.php).
Results and discussion
The expression and purification of the recombinant extracellular matrix protein mindin
Humoral immune responses are induced by vaccination with antigens combined with different adjuvants
The cellular immune responses of a splenocyte proliferation assay in vitro
T. gondiiantigens combined with mindin elicited protective immunity against a lethal challenge in BALB/c mice
This study has proven that the extracellular matrix protein mindin acts as a potent vaccine adjuvant, which could enhance both humoral and cellular immune responses against Toxoplasma infection. The precise mechanism by which mindin promotes immune responses, however, remains open to further investigation.
This present study was financially supported by the National Natural Science Foundation of China to Qijun Chen (grant number 81130033) and to Ning Jiang (grant number 81171592), and the provincial Natural Science Foundation of Jilin Province, China to Ning Jiang (grant number 20140101034JC). Special thanks to the staff of the Department of Laboratory Animals of Jilin University for kind assistance in animal immunization, serum collection. We also thank the staff of the professional English language service (American Journal experts, http://www.aje.com/) for the medical writing services.
- Slingluff CL, Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, Petroni G, Cohen R, Wiernasz C, Patterson JW, Conway BP, Ross WG: Phase I trial of a melanoma vaccine with gp100(280–288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001, 7 (10): 3012-3024.PubMedGoogle Scholar
- Klar A, Baldassare M, Jessell TM: F-spondin: a gene expressed at high levels in the floor plate encodes a secreted protein that promotes neural cell adhesion and neurite extension. Cell. 1992, 69 (1): 95-110.View ArticlePubMedGoogle Scholar
- Higashijima S, Nose A, Eguchi G, Hotta Y, Okamoto H: Mindin/F-spondin family: novel ECM proteins expressed in the zebrafish embryonic axis. Dev Biol. 1997, 192 (2): 211-227.View ArticlePubMedGoogle Scholar
- Umemiya T, Takeichi M, Nose A: M-spondin, a novel ECM protein highly homologous to vertebrate F-spondin, is localized at the muscle attachment sites in the Drosophila embryo. Dev Biol. 1997, 186 (2): 165-176.View ArticlePubMedGoogle Scholar
- Feinstein Y, Borrell V, Garcia C, Burstyn-Cohen T, Tzarfaty V, Frumkin A, Nose A, Okamoto H, Higashijima S, Soriano E, Klar A: F-spondin and mindin: two structurally and functionally related genes expressed in the hippocampus that promote outgrowth of embryonic hippocampal neurons. Development. 1999, 126 (16): 3637-3648.PubMedGoogle Scholar
- Jia W, Li H, He YW: Pattern recognition molecule mindin promotes intranasal clearance of influenza viruses. J Immunol. 2008, 180 (9): 6255-6261.View ArticlePubMedGoogle Scholar
- McDonald C, Nunez G: Mindin the fort. Nat Immunol. 2004, 5 (1): 16-18.View ArticlePubMedGoogle Scholar
- He YW, Li H, Zhang J, Hsu CL, Lin E, Zhang N, Guo J, Forbush KA, Bevan MJ: The extracellular matrix protein mindin is a pattern-recognition molecule for microbial pathogens. Nat Immunol. 2004, 5 (1): 88-97.View ArticlePubMedGoogle Scholar
- Tenter AM, Heckeroth AR, Weiss LM: Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000, 30 (12–13): 1217-1258.View ArticlePubMedPubMed CentralGoogle Scholar
- Cenci-Goga BT, Rossitto PV, Sechi P, McCrindle CM, Cullor JS: Toxoplasma in animals, food, and humans: an old parasite of new concern. Foodborne Pathog Dis. 2010, 8 (7): 751-762.View ArticleGoogle Scholar
- Innes EA, Bartley PM, Buxton D, Katzer F: Ovine toxoplasmosis. Parasitology. 2009, 136 (14): 1887-1894.View ArticlePubMedGoogle Scholar
- Montoya JG, Liesenfeld O: Toxoplasmosis. Lancet. 2004, 363 (9425): 1965-1976.View ArticlePubMedGoogle Scholar
- Meng M, He S, Zhao G, Bai Y, Zhou H, Cong H, Lu G, Zhao Q, Zhu XQ: Evaluation of protective immune responses induced by DNA vaccines encoding Toxoplasma gondiisurface antigen 1 (SAG1) and 14-3-3 protein in BALB/c mice. Parasit Vectors. 2012, 5 (1): 273-View ArticlePubMedPubMed CentralGoogle Scholar
- Havelaar AH, Kemmeren JM, Kortbeek LM: Disease burden of congenital toxoplasmosis. Clin Infect Dis. 2007, 44 (11): 1467-1474.View ArticlePubMedGoogle Scholar
- Buxton D, Thomson K, Maley S, Wright S, Bos HJ: Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnant. Vet Rec. 1991, 129 (5): 89-93.View ArticlePubMedGoogle Scholar
- Ismael AB, Sekkai D, Collin C, Bout D, Mevelec MN: The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis. Infect Immun. 2003, 71 (11): 6222-6228.View ArticlePubMedPubMed CentralGoogle Scholar
- Tomavo S: The major surface proteins of Toxoplasma gondii: structures and functions. Curr Top Microbiol Immunol. 1996, 219: 45-54.PubMedGoogle Scholar
- He XL, Grigg ME, Boothroyd JC, Garcia KC: Structure of the immunodominant surface antigen from the Toxoplasma gondii SRS superfamily. Nat Struct Biol. 2002, 9 (8): 606-611.PubMedGoogle Scholar
- Kim SK, Boothroyd JC: Stage-specific expression of surface antigens by Toxoplasma gondii as a mechanism to facilitate parasite persistence. J Immunol. 2005, 174 (12): 8038-8048.View ArticlePubMedGoogle Scholar
- Lunden A, Parmley SF, Bengtsson KL, Araujo FG: Use of a recombinant antigen, SAG2, expressed as a glutathione-S-transferase fusion protein to immunize mice against Toxoplasma gondii. Parasitol Res. 1997, 83 (1): 6-9.PubMedGoogle Scholar
- Howe DK, Crawford AC, Lindsay D, Sibley LD: The p29 and p35 immunodominant antigens of Neospora caninum tachyzoites are homologous to the family of surface antigens of Toxoplasma gondii. Infect Immun. 1998, 66 (11): 5322-5328.PubMedPubMed CentralGoogle Scholar
- Bohne W, Gross U, Ferguson DJ, Heesemann J: Cloning and characterization of a bradyzoite-specifically expressed gene (hsp30/bag1) of Toxoplasma gondii, related to genes encoding small heat-shock proteins of plants. Mol Microbiol. 1995, 16 (6): 1221-1230.View ArticlePubMedGoogle Scholar
- Parmley SF, Weiss LM, Yang S: Cloning of a bradyzoite-specific gene of Toxoplasma gondii encoding a cytoplasmic antigen. Mol Biochem Parasitol. 1995, 73 (1–2): 253-257.View ArticlePubMedGoogle Scholar
- Di Cristina M, Del Porto P, Buffolano W, Beghetto E, Spadoni A, Guglietta S, Piccolella E, Felici F, Gargano N: The Toxoplasma gondii bradyzoite antigens BAG1 and MAG1 induce early humoral and cell-mediated immune responses upon human infection. Microbes Infect. 2004, 6 (2): 164-171.View ArticlePubMedGoogle Scholar
- Sun X, Lu H, Jia B, Chang Z, Peng S, Yin J, Chen Q, Jiang N: A comparative study of Toxoplasma gondii seroprevalence in three healthy Chinese populations detected using native and recombinant antigens. Parasit Vectors. 2013, 6 (1): 241-View ArticlePubMedPubMed CentralGoogle Scholar
- Du C, Nilsson S, Lu H, Yin J, Jiang N, Wahlgren M, Chen Q: Immunogenicity of the Plasmodium falciparum Pf332-DBL domain in combination with different adjuvants. Vaccine. 2010, 28 (31): 4977-4983.View ArticlePubMedGoogle Scholar
- Chuang SC, Ko JC, Chen CP, Du JT, Yang CD: Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles. Parasit Vectors. 2013, 6 (1): 34-View ArticlePubMedPubMed CentralGoogle Scholar
- Hauser WE, Remington JS: Effect of monoclonal antibodies on phagocytosis and killing of Toxoplasma gondii by normal macrophages. Infect Immun. 1981, 32 (2): 637-640.PubMedPubMed CentralGoogle Scholar
- Johnson AM, McDonald PJ, Neoh SH: Monoclonal antibodies to Toxoplasma cell membrane surface antigens protect mice from toxoplasmosis. J Protozool. 1983, 30 (2): 351-356.View ArticlePubMedGoogle Scholar
- Mineo JR, Khan IA, Kasper LH: Toxoplasma gondii: a monoclonal antibody that inhibits intracellular replication. Exp Parasitol. 1994, 79 (3): 351-361.View ArticlePubMedGoogle Scholar
- Yap GS, Sher A: Cell-mediated immunity to Toxoplasma gondii: initiation, regulation and effector function. Immunobiology. 1999, 201 (2): 240-247.View ArticlePubMedGoogle Scholar
- Stutz A, Kessler H, Kaschel ME, Meissner M, Dalpke AH: Cell invasion and strain dependent induction of suppressor of cytokine signaling-1 by Toxoplasma gondii. Immunobiology. 2012, 217 (1): 28-36.View ArticlePubMedGoogle Scholar
- Dallman MJ: Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Curr Opin Immunol. 1995, 7 (5): 632-638.View ArticlePubMedGoogle Scholar
- Cleary MD, Singh U, Blader IJ, Brewer JL, Boothroyd JC: Toxoplasma gondii asexual development: identification of developmentally regulated genes and distinct patterns of gene expression. Eukaryot Cell. 2002, 1 (3): 329-340.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/14/429/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.